# The Effects of Evolocumab in Patients With Diabetes and Atherosclerotic Vascular Disease

> **NCT03829046** · PHASE4 · COMPLETED · sponsor: **Robert Rosenson** · enrollment: 41 (actual)

## Conditions studied

- Atherosclerotic Vascular Disease
- Type2 Diabetes
- Microvascular Dysfunction

## Interventions

- **DRUG:** Placebo
- **DRUG:** Evolocumab

## Key facts

- **NCT ID:** NCT03829046
- **Lead sponsor:** Robert Rosenson
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-03
- **Primary completion:** 2021-11-15
- **Final completion:** 2021-11-15
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2026-04-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03829046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03829046, "The Effects of Evolocumab in Patients With Diabetes and Atherosclerotic Vascular Disease". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03829046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*